e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

Chronic Management of Depression: A Comprehensive Review

BH.Sri Vaishnavi | K.Vaishnavi

Vignan Institute of Pharmaceutical Technology(A), Duvvada,530049, India
Corresponding mail id: bhsrivaishnavi23@gmail.com

Received: 15 July 2025 | **Revised & Accepted:** 11 November 2025

Keywords : depression, chronic disorder, cognitive behaviour therapy, psychology.

Abstract

Major depressive disorder is a major cause of disability across the world as they run in recurrent periods accompanied by a chronic pattern in a significant number of patients. Treatment of depression should be multifaceted which should involve pharmacological interventions and psychological interventions, social interventions and emerging biological approaches. The review summarizes the current development in the treatment and research of chronic depression focusing on evidence-based approaches, the significance of early and prolonged remission as well as incorporation of innovative treatment medicines and personalized medicine.

Introduction

Major depression is a heterogeneous, complex and often chronic disorder with a significant personal, social as well as economic impact.[1] However, with improvement in acute care, a significant number of patients have chronic symptoms, frequent relapses or experience incomplete recovery and there is a need to find effective strategies of chronic management. This review offers a comprehensive treatment of the chronic management of depression, which uses only the new and high-calibre sources.[2]

Epidemiology and Burden of Chronic Depression

Prevalence and Impact

MDD experience is estimated at the level of 10-20%, with the chronic course developing in 20-30% of patients.[3]

Chronic depression is linked with risk of comorbidities, functional deficit, low quality of life and high risk of suicide.[4]

The economic cost is tremendous, and the utilization of the healthcare resources, lost productivity, and disability contribute to the expenditures both directly and indirectly.[5]

Prognosis and Course

MDD can be recurring and chronic: maximum 80 percent of the patients have more than one episode, and as far as 20 percent acquire chronic symptoms of two years or above.

Early onset, increased severity, comorbid psychiatric or medical problems and insufficient response to treatment are related to chronicity.[6]

Chronicity and pathophysiology

Neurobiological Mechanisms

Immune system dysregulation (inflammation, neurotrophic factors, neuroplasticity) plays a vital role in chronic depression, however the neurotransmitter dysregulation (serotonin, norepinephrine,

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

dopamine) continues to be the core of depression conditions.[7]

Chronic cases are observed to have altered brain activity within cortex frontal, amygdala, and hippocampus areas which still continues to change even when in remission. [8]

Between genetic and epigenetic determinants, there is some contribution to chronicity in playing a role in susceptibility, course, and treatment response.[9]

Psychosocial and Environmental Feeds Goals

Achieve and sustain remission (not just response).

Prevent relapse and recurrence.[10]

Restore functioning and quality of life.

Minimize adverse effects and improve treatment adherence.[11]

Chronic Care Model

Emphasizes long-term monitoring, patient education, collaborative care, and integration of medical and psychosocial interventions.[12]

Pharmacological Management

Antidepressant Strategies

First-Line Agents

SSRIs, SNRIs, and atypical antidepressants remain first-line for chronic depression.13

Long-term use is often necessary, with maintenance therapy recommended for those with recurrent or chronic courses.[14]

Augmentation and Combination

For partial or non-response, augmentation with atypical antipsychotics, lithium, or thyroid hormone may be considered.

Combination therapy (e.g., antidepressant plus psychotherapy) is often more effective for chronic depression.[15]

Novel and Emerging Agents

There has been success Esketamine and psilocybin have proved useful in treatment-resistant and chronic depression, but long-term safety and effectivity remains to be studied.[16]

Pharmacogenomics testing can aid prescribers in selecting specific medications and is designed to enhance results.[17]

Adherence, and Control of Side Effects

The treatment of the side effects and simplification of the regimens are important considerations to long-term adherence. Monitoring of metabolic, sexual, and cognitive side effects should be regularly taken.[18]

Psychological and Psychosocial Interventions

Evidence-Based Psychotherapies

Cognitive Behavioural Therapy (CBT)

CBT is used in the acute and maintenance stages as it decreases the rate of relapse and leads to recovery in the long-term scenario.[19]

Mindfulness based cognitive therapy (MBCT)

MBCT is effective with people who have cases of recurrent or chronic depression, in preventing these problems occur again.[20]

Other Therapies Other than Interpersonal Therapy (IPT)

IPT and other structured therapies (e.g, behavioural activation, problem-solving therapy) are effective, and this particularly occurs when they are included in long-term care.[21]

Social and Functional Rehabilitation

Functioning can be enhanced by social skills training, vocational rehabilitation,

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

and family interventions and chronicity diminished.

Comorbidity (anxiety, substance use, and medical conditions) should also be treated to manage the problem.[22]

Treatment of Biological and Neuromodulation

Electroconvulsive Therapy (ECT)

ECT can be considered as the best intervention in major depression, refractory/ psychotic depression, and the chronic form.[23]

Repetitive Transcranial Magnetic Stimulation (rTMS)

rTMS is effective non-invasive therapy that is safe, tolerable, and useful as a treatment of chronic and treatment-resistant depression and also has some evidence regarding its effectiveness as a maintenance therapy.[24]

Other therapies Vagus Nerve Stimulation (VNS)

VNS and other neuromodulation procedures are becoming adjuncts used on chronic, refractory cases but are not widespread or available or extensively studied over long-term use.[25]

Individualised vetting and Precision Medicine

Pharmacogenomics

pharmacogenomic test may reveal gene-drug relationships, make decisions about drugs, and enhance remission rates in people with chronic depression.[26]

Neuroimaging, and Biomarkers

Improvements in biomarkers (ex: inflammatory markers, neurotrophins) and neuroimaging could facilitate the early prediction of risk of chronicity and can be involved in individualized interventions.[27]

Relapse and recurrence intervention

Persistent depressive symptoms are associated with childhood adversity, chronic stress and social isolation.[28]

Chronicity is escalated and recovery is thwarted by poor social functioning and lack of support.[29]

Chronic Management Principles

Goals

Achieve remission and maintain this. (Not only response.)

Avert recurrence and relapse.[30]

Retrieve functioning and quality of life

Reduce maladies and increase tolerance to treatment.

Chronic Care Model

Focuses on monitoring (long-term), patient education, cooperative care, and combining medical and psychosocial interventions.[31]

Pharmacological Management

Antidepressant Strategies

The Working first-line agents

SSRI, SNRI and atypical antidepressants are first-line drugs in chronic depression.[32]

It is commonly assumed that long-term treatment is required, and maintenance therapy should also be administered in the case of recurrent or chronic courses.[33]

Patients with long-standing or recurrent depression should be advised to continue (at least 6 and up to 24 months or even longer) maintenance antidepressant treatment.[34]

Psychotherapy during maintenance minimizes the likelihood of relapse particularly in individuals who have had several prior times.

Trajectory and Disease Remission Early

Predominantly achieving and maintaining early remission is linked to improved longer term outcomes and lowered chronicity.[35]

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

Slow or partial remission indicates increased chance of relapse and unremitted symptoms.[36]

Special Populations and Considerations

Elderly Patients

Chronic depression is more common in the older age, and is associated with the higher risk of cognitive decline, medical comorbidity and functional impairment.

Different approaches, close attention to side effects, and consorted care is a necessity.[37]

Young people and Young-Onset Depression

The early-onset depression is more likely to develop into chronic continuous one that requires early intervention and persistent long-term follow-up.[38]

Medical and Psychiatric Comorbidity

Chronic depression treatment Comorbidity management (e.g. cardiovascular disease, diabetes, anxiety, substance use) is part of chronic depression management.39

The collaborative care models enhance the outcomes in patients with complex comorbidities.[40]

Functional Recovery and Social Determinants

Socioeconomic Factors

Both unemployment and poverty and social isolation are the risk factors of chronicity and an intervention subject.[41]

Policy and community involvement are important in dealing with social determinants toward sustainable recovery.[42]

Functional Outcomes

One of the major aims is the restoration of social and occupational functioning; the interventions must not only focus on symptom remission but also on the functional improved outcome.[43]

System and Economical Choices

Cost-Effectiveness

Chronic depression has a huge economic impact on the individual and the society with the expenditures being compounded on healthcare usage, lack of productivity and disability.44

Integrated models, collaborative care, and stepped care are low-cost methods of chronic management.[45]

The Integration of the Healthcare Systems

Chronic care models give more focus on chronic monitoring and coordination as well as integration of medical and psychosocial services.

Telehealth and digital intervention are also more significant factors in access and continuous care.[46]

Future Directions

Novel Therapeutics

The new neuro-advances will be promising in chronic and treatment-resistant depression, including psychedelics (psilocybin), rapid-acting antidepressants (esketamine), and neurostimulation.[47]

Precision Psychiatry

Combination of genomics, biomarkers, and digital phenotyping has the potential to allow more specific care especially in chronic conditions to be more personalized.[48]

Policy and Advocacy

More attention on prevention, early intervention and social determiner is required to ease down the burden of chronic depression.[49]

Conclusion

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

Treatment of depression as a chronic illness is a dynamic, multidimensional problem that needs long-term, multidisciplinary, and individual plans. The current progress with regard to pharmacology, psychotherapy, neuromodulation, and precision medicine in mental neurology creates the promise of obtaining better long-term results. Primary observances must be early remission, relapse prevention and re-establish functioning. Depression has a lasting burden that needs to be minimized by consistent research, system-level change, and consideration of societal determinants.

References

1. Monroe, Scott M., Anderson, Samantha F.. Depression. Current Directions in Psychological Science. 2015;24(3):227-231. doi:https://doi.org/10.1177/0963721414568342
2. Davy, Carol, Bleasel, Jonathan, Liu, Hueiming, Tchan, Maria, Ponniah, Sharon, Brown, Alex. Effectiveness of chronic care models: opportunities for improving healthcare practice and health outcomes: a systematic review. BMC Health Services Research. 2015;15(1). doi:https://doi.org/10.1186/s12913-015-0854-8
3. Judd, Lewis L., Akiskal, Hagop S., Maser, Jack D., Zeller, Pamela J., Endicott, Jean, Coryell, William, Paulus, Martin P., Kunovac, Jelena L., Leon, Andrew C., Mueller, Timothy I., Rice, John A., Keller, Martin B.. A Prospective 12-Year Study of Subsyndromal and Syndromal Depressive Symptoms in Unipolar Major Depressive Disorders. Archives of General Psychiatry. 1998;55(8):694. doi:https://doi.org/10.1001/archpsyc.55.8.694
4. Kim, Hyunji, Kim, Sung Hi, Cho, Yoon Jeong. Combined Effects of Depression and Chronic Disease on the Risk of Mortality: The Korean Longitudinal Study of Aging (2006-2016). Journal of Korean Medical Science. 2021;36(16). doi:https://doi.org/10.3346/jkms.2021.36.e99
5. Gandjour, Afschin. Long COVID: Costs for the German economy and health care and pension system. BMC Health Services Research. 2023;23(1). doi:https://doi.org/10.1186/s12913-023-09601-6
6. Patten, Scott B.. RECURRENCE RISK IN MAJOR DEPRESSION. Depression and Anxiety. 2012;30(1):1-4. doi:https://doi.org/10.1002/da.22030
7. Jiao, Wenli, Lin, Jiayi, Deng, Yanfang, Ji, Yelin, Liang, Chuoyi, Wei, Sijia, Jing, Xi, Yan, Fengxia. The immunological perspective of major depressive disorder: unveiling the interactions between central and peripheral immune mechanisms. Journal of Neuroinflammation. 2025;22(1). doi:https://doi.org/10.1186/s12974-024-03312-3
8. Barnden, Leighton R., Crouch, Benjamin, Kwiatek, Richard, Burnet, Richard, Del Fante, Peter. Evidence in chronic fatigue syndrome for severity-dependent upregulation of prefrontal myelination that is independent of anxiety and depression. NMR in Biomedicine. 2015;28(3):404-413. doi:https://doi.org/10.1002/nbm.3261
9. Addissouky, Tamer A., El Tantawy El Sayed, Ibrahim, Wang, Yuliang. Epigenetic factors in posttraumatic stress disorder resilience and susceptibility. Egyptian Journal of Medical Human Genetics. 2025;26(1).

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

doi:https://doi.org/10.1186/s43042-025-00684-w

10. Cosci, Fiammetta, Mansueto, Giovanni, Fava, Giovanni Andrea. Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. International Journal of Psychiatry in Clinical Practice. 2020;24(4):341-348. doi:https://doi.org/10.1080/13651501.2020.1779308
11. Fujii, Hironori, Ueda, Yukino, Hirose, Chiemi, Ohata, Koichi, Sekiya, Kumiko, Kitahora, Mika, Sadaka, Shiori, Yamamoto, Senri, Watanabe, Daichi, Kato-Hayashi, Hiroko, Iihara, Hirotoshi, Kobayashi, Ryo, Kaburaki, Miho, Matsuhashi, Nobuhisa, Takahashi, Takao, Makiyama, Akitaka, Yoshida, Kazuhiro, Hayashi, Hideki, Suzuki, Akio. Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. Journal of Pharmaceutical Health Care and Sciences. 2022;8(1). doi:https://doi.org/10.1186/s40780-022-00239-w
12. Cramm, Jane Murray, Nieboer, Anna Petra. The chronic care model: congruency and predictors among patients with cardiovascular diseases and chronic obstructive pulmonary disease in the Netherlands. BMC Health Services Research. 2012;12(1). doi:https://doi.org/10.1186/1472-6963-12-242
13. Woo, Young Sup, Bahk, Won-Myong, Seo, Jeong Seok, Park, Young-Min, Kim, Won, Jeong, Jong-Hyun, Shim, Se-Hoon, Lee, Jung Goo, Jang, Seung-Ho, Yang, Chan-Mo, Wang, Sheng-Min, Jung, Myung Hun, Sung, Hyung Mo, Choo, Il Han, Yoon, Bo-Hyun, Lee, Sang-Yeol, Jon, Duk-In, Min, Kyung Joon. The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines. Clinical Psychopharmacology and Neuroscience. 2022;20(1):37-50. doi:https://doi.org/10.9758/cpn.2022.20.1.37
14. Ehret, Megan J., Levin, Gary M.. Long-term Use of Atypical Antipsychotics in Bipolar Disorder. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2006;26(8):1134-1147. doi:https://doi.org/10.1592/phco.26.8.1134
15. Bassett, Darryl, Parker, Gordon, Hamilton, Amber, Morris, Grace, Baune, Bernhard T, Boyce, Philip, Hopwood, Malcolm, Mulder, Roger, Porter, Richard, Singh, Ajeet, Outhred, Tim, Mannie, Zola, Das, Pritha, Malhi, Gin S. Treatment-resistant depressive disorders: The when, how and what of augmentation therapy. Australian & New Zealand Journal of Psychiatry. 2019;53(3):187-189. doi:https://doi.org/10.1177/0004867419828483
16. Salahudeen, Mohammed S, Wright, Cameron M, Peterson, Gregory M. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Therapeutic Advances in Drug Safety. 2020;11. doi:https://doi.org/10.1177/2042098620937899
17. Weitzel, Kristin Wiisanen, Duong, Benjamin Q, Arwood, Meghan J, Owusu-Obeng, Aniwaa, Abul-Husn, Noura S, Bernhardt, Barbara A, Decker, Brian, Denny, Joshua C, Dietrich, Eric,

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

Gums, John, Madden, Ebony B, Pollin, Toni I, Wu, Rebekah Ryanne, Haga, Susanne B, Horowitz, Carol R. A Stepwise Approach to Implementing Pharmacogenetic Testing in the Primary Care Setting. Pharmacogenomics. 2019;20(15):1103-1112. doi:https://doi.org/10.2217/pgs-2019-0053

18. Weitzel, Kristin Wiisanen, Duong, Benjamin Q, Arwood, Meghan J, Owusu-Obeng, Aniwaa, Abul-Husn, Noura S, Bernhardt, Barbara A, Decker, Brian, Denny, Joshua C, Dietrich, Eric, Gums, John, Madden, Ebony B, Pollin, Toni I, Wu, Rebekah Ryanne, Haga, Susanne B, Horowitz, Carol R. A Stepwise Approach to Implementing Pharmacogenetic Testing in the Primary Care Setting. Pharmacogenomics. 2019;20(15):1103-1112. doi:https://doi.org/10.2217/pgs-2019-0053
19. DiBonaventura, Marco, Gabriel, Susan, Dupclay, Leon, Gupta, Shaloo, Kim, Edward. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1). doi:https://doi.org/10.1186/1471-244x-12-20
20. Stangier, Ulrich, Hilling, Christine, Heidenreich, Thomas, Risch, Anne Katrin, Barocka, Arnd, Schlösser, Ralf, Kronfeld, Kai, Ruckes, Christian, Berger, Hartmut, Röschke, Joachim, Weck, Florian, Volk, Stephan, Hambrecht, Martin, Serfling, Richard, Erkwoh, Ralf, Stirn, Aglaja, Sobanski, Thomas, Hautzinger, Martin. Maintenance Cognitive-Behavioral Therapy and Manualized Psychoeducation in the Treatment of Recurrent Depression: A Multicenter Prospective Randomized Controlled Trial. American Journal of Psychiatry. 2013;170(6):624-632. doi:https://doi.org/10.1176/appi.ajp.2013.12060734
21. White, Nicole D.. Mindfulness-Based Cognitive Therapy for Depression, Current Episodes, and Prevention of Relapse. American Journal of Lifestyle Medicine. 2015;9(3):227-229. doi:https://doi.org/10.1177/1559827615569677
22. Braun, Sarah R., Gregor, Bettina, Tran, Ulrich S.. Comparing Bona Fide Psychotherapies of Depression in Adults with Two Meta-Analytical Approaches. PLoS ONE. 2013;8(6):e68135. doi:https://doi.org/10.1371/journal.pone.0068135
23. Farkas, Marianne, Anthony, William A.. Psychiatric rehabilitation interventions: A review. International Review of Psychiatry. 2010;22(2):114-129. doi:https://doi.org/10.3109/09540261003730372
24. Kellner, Charles H., Greenberg, Robert M., Murrough, James W., Bryson, Ethan O., Briggs, Mimi C., Pasculli, Rosa M.. ECT in Treatment-Resistant Depression. American Journal of Psychiatry. 2012;169(12):1238-1244. doi:https://doi.org/10.1176/appi.ajp.2012.12050648
25. Voigt, Jeffrey, Carpenter, Linda, Leuchter, Andrew. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. BMC Psychiatry. 2019;19(1). doi:https://doi.org/10.1186/s12888-018-1989-z

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

26. Markert, Matthew S., Fisher, Robert S.. Neuromodulation - Science and Practice in Epilepsy: Vagus Nerve Stimulation, Thalamic Deep Brain Stimulation, and Responsive NeuroStimulation. Expert Review of Neurotherapeutics. 2018;19(1):17-29. doi:https://doi.org/10.1080/14737175.2019.1554433
27. McCarthy, Michael J, Chen, Yucui, Demodena, Anna, Leckband, Susan G, Fischer, Eileen, Golshan, Shahrokh, Suppes, Trisha, Kelsoe, John R. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. Journal of Psychopharmacology. 2021;35(8):992-1002. doi:https://doi.org/10.1177/0269881121101522 4
28. Pozo-Rosich, Patricia, Coppola, Gianluca, Pascual, Julio, Schwedt, Todd J. How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia. 2020;41(5):613-630. doi:https://doi.org/10.1177/0333102420974359
29. Lye, Munn-Sann, Tey, Yin-Yee, Tor, Yin-Sim, Shahabudin, Aisya Farhana, Ibrahim, Normala, Ling, King-Hwa, Stanslas, Johnson, Loh, Su-Peng, Rosli, Rozita, Lokman, Khairul Aiman, Badamasi, Ibrahim Mohammed, Faris-Aldoghachi, Asraa, Abdul Razak, Nurul Asyikin. Predictors of recurrence of major depressive disorder. PLOS ONE. 2020;15(3):e0230363. doi:https://doi.org/10.1371/journal.pone.0230363
30. Nørup, Iben. Social marginalization and chronic illness: A critical analysis of the role of labour-market exclusion. Acta Sociologica. 2019;63(2):173-190. doi:https://doi.org/10.1177/0001699318821429
31. Audulv, Åsa. The over time development of chronic illness self-management patterns: a longitudinal qualitative study. BMC Public Health. 2013;13(1). doi:https://doi.org/10.1186/1471-2458-13-452
32. Cramm, Jane Murray, Nieboer, Anna Petra. Chronically ill patients' self-management abilities to maintain overall well-being: what is needed to take the next step in the primary care setting?. BMC Family Practice. 2015;16(1). doi:https://doi.org/10.1186/s12875-015-0340-8
33. Woodall, Alan, Walker, Lauren. A guide to prescribing antidepressants in primary care. Prescriber. 2022;33(8-9):11-18. doi:https://doi.org/10.1002/psb.2006
34. Unknown Author. Continuation drug therapy for major depressive episodes: how long should it be maintained?. American Journal of Psychiatry. 1986;143(1):18-23. doi:https://doi.org/10.1176/ajp.143.1.18
35. Bauer, Michael, Severus, Emanuel, Köhler, Stephan, Whybrow, Peter C., Angst, Jules, Möller, Hans-Jürgen, undefined, undefined. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015. The World Journal of Biological Psychiatry. 2015;16(2):76-95. doi:https://doi.org/10.3109/15622975.2014.1001786

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

36. Cosci, Fiammetta, Guidi, Jenny, Mansueto, Giovanni, Fava, Giovanni A.. Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations. Expert Review of Neurotherapeutics. 2020;20(11):1169-1175. doi:https://doi.org/10.1080/14737175.2020.1804870
37. Yeh, Mei-Yu, Lee, Yu, Sung, Su-Ching, Tung, Tao-Hsin. Clinical predictors associated with full remission versus episode of major depressive disorder outpatients: the experience at a teaching hospital in Taiwan. BMC Psychiatry. 2014;14(1). doi:https://doi.org/10.1186/s12888-014-0273-0
38. Vaid, Nasreen. Depression in the elderly. InnovAiT: Education and inspiration for general practice. 2015;8(9):555-561. doi:https://doi.org/10.1177/1755738015596030
39. Schubert, Klaus Oliver, Clark, Scott R, Van, Linh K, Collinson, Jane L, Baune, Bernhard T. Depressive symptom trajectories in late adolescence and early adulthood: A systematic review. Australian & New Zealand Journal of Psychiatry. 2017;51(5):477-499. doi:https://doi.org/10.1177/0004867417700274Koike, Alan K., Unützer, Jürgen, Wells, Kenneth B.. Improving the Care for Depression in Patients With Comorbid Medical Illness. American Journal of Psychiatry. 2002;159(10):1738-1745. doi:https://doi.org/10.1176/appi.ajp.159.10.1738
40. Liu, Meixin, Wang, Yuanhong. S1P receptor 1 antagonist ponesimod alleviates postherpetic neuralgia in rats by normalizing spinal TRPV1 expression and inhibiting MAPK-mediated glial activation.. Cytotechnology. 2025;77(4):141. doi:https://doi.org/10.1007/s11920-014-0506-4.pdf
41. Rethorn, Zachary D., Cook, Chad, Reneker, Jennifer C.. Social Determinants of Health: If You Aren't Measuring Them, You Aren't Seeing the Big Picture. Journal of Orthopaedic & Sports Physical Therapy. 2019;49(12):872-874. doi:https://doi.org/10.2519/jospt.2019.0613
42. Walker, Sarah Cusworth, White, Johnna, Rodriguez, Victor, Turk, Emily, Gubner, Noah, Ngo, Sally, Bekemeier, Betty. Cocreating evidence-informed health equity policy with community. Health Services Research. 2022;57(S1):137-148. doi:https://doi.org/10.1111/1475-6773.13940
43. Greer, Tracy L., Kurian, Benji T., Trivedi, Madhukar H.. Defining and Measuring Functional Recovery from Depression. CNS Drugs. 2010;24(4):267-284. doi:https://doi.org/10.2165/11530230-000000000-00000
44. Pirraglia, Paul A., Rosen, Allison B., Hermann, Richard C., Olchanski, Natalia V., Neumann, Peter. Cost-Utility Analysis Studies of Depression Management: A Systematic Review. American Journal of Psychiatry. 2004;161(12):2155-2162. doi:https://doi.org/10.1176/appi.ajp.161.12.2155
45. Ee, C., Lake, J., Firth, J., Hargraves, F., de Manincor, M., Meade, T., Marx, W., Sarris, J.. An integrative collaborative care model for people with mental illness and physical comorbidities. International Journal of Mental Health Systems. 2020;14(1).

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 05 | May 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0426007

doi:https://doi.org/10.1186/s13033-020-00410-6

46. Fortin, Martin, Chouinard, Maud-Christine, Bouhali, Tarek, Dubois, Marie-France, Gagnon, Cynthia, Bélanger, Martin. Evaluating the integration of chronic disease prevention and management services into primary health care. BMC Health Services Research. 2013;13(1). doi:https://doi.org/10.1186/1472-6963-13-132
47. Cooper, Takesha, Seigler, Michael David, Stahl, Stephen. Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions. Journal of Psychopharmacology. 2023;37(3):242-247. doi:https://doi.org/10.1177/02698811231158891
48. Fernandes, Brisa S., Williams, Leanne M., Steiner, Johann, Leboyer, Marion, Carvalho, André F., Berk, Michael. The new field of 'precision psychiatry'. BMC Medicine. 2017;15(1). doi:https://doi.org/10.1186/s12916-017-0849-x
49. Compton, Michael T., Shim, Ruth S.. Mental Illness Prevention and Mental Health Promotion: When, Who, and How. Psychiatric Services. 2020;71(9):981-983. doi:https://doi.org/10.1176/appi.ps.201900374

© BTS Pharma Empire All Rights Reserved